> ## Content Index > Fetch the complete content index at: https://www.biostockinfo.com/llms.txt > Use this file to discover other available public pages before exploring further. # Q1 2026 Performance Check for AI Catalyst Scanner - URL: https://www.biostockinfo.com/q1-2026-performance-check-for-ai-catalyst-scanner/ - Published: 2026-05-08T13:25:30.000Z - Updated: 2026-05-08T13:30:17.000Z - Author: Alex - Tags: AI, Biotech Investing, Catalyst Scanner, Catalyst, Machine Learning, Scanner, Performance I'm sharing the Q1 2026 performance data for the BSI AI Catalyst Scanner, covering all weekly scans from **January Week 1 through March Week 4** — 12 weekly scans and 115 total top-10 picks tracked. Before going into the numbers, one framing point that I want to be explicit about: **this performance data does not — and is not intended to — prove that the BSI AI Catalyst Scanner is a reliable tool to be used on its own for investment decision-making.** The scanner's main purpose is to help readers identify potential near-term investment opportunities surrounding known and estimated catalysts roughly 45 days ahead of each weekly scan. It is one input into a broader research process, not a substitute for it. As the data clearly shows, very few gains are maintained long term, and despite some strong win rates inside the 45-day window, the min/max range during that same period is enormous. I've also included **market-cap-at-pick data** for every ticker this quarter — a new addition to the dataset, added per a subscriber's request. ## Q1 2026 Highlights Out of **115 picks** during the three-month period: - **77 tickers (67%)** posted gains of **over 15%** within 45 days of being posted. - **31 tickers (27%)** posted gains of **over 30%** within the same 45-day window. - Only **46 tickers (40%)** are currently in positive territory at the time of this article. - Only **36 tickers (31%)** are still up more than 10% today. The gap between those four numbers is the whole story. A 67% hit rate at the +15% threshold within 45 days is a meaningful signal that the scanner is consistently surfacing names with short-term upside around catalyst events. But the drop from 67% peak to 40% currently green tells you very directly that **most of these gains are not held long term.** Catalyst-driven biotech names spike and fade — that is the market structure they trade in, not a bug in the scanner. The same dataset also shows huge intraperiod swings. It is entirely normal for a single name to print +50% peak and -30% trough inside the very same 45-day window. Without a plan for what to do when either of those things happens, the scanner alone is of limited use. ## How to Actually Use This Data As I mentioned in [my previous post on performance data](https://www.biostockinfo.com/ai-weekly-scanner-performance-check/), the conclusions reinforce what I keep coming back to, and they are worth repeating: 1. **Monitor price action closely** with any investment made around a catalyst. Catalyst windows compress weeks of price discovery into days, sometimes hours. 2. **Tight stop losses are highly recommended.** The 45-day average drawdown across this dataset is significantly negative. Without a defined downside cap, peak gains evaporate quickly. 3. **A clear exit strategy is absolutely necessary** — decided in advance, before entry. The data above shows that holding through the peak and into the fade is the dominant failure mode. 4. **Thorough due diligence is always necessary** with any investment. The scanner identifies the opportunity set; it does not assess management quality, balance-sheet health, trial design, or competitive positioning. That part is on you. ## A Note on Data Exclusion *One ticker has been removed from this quarter's dataset: *Helus Pharma (HELP, ex-Cybin)*. The source price file for HELP contained mixed-currency data — USD on some days and CAD on others — which made the performance metrics unreliable enough that I would rather exclude it than publish a misleading data point. For the record, Helus did have a nice (if short-lived) run surrounding the U.S. government decision on psychedelics during the quarter. The exclusion is a data-integrity call, not a commentary on the company itself.* Below table is best viewed on a tablet or on a desktop. Q1 2026 ## — of Q1 picks gained 15%+ within 45 days A full quarterly review of all top-10 BSI scanner picks from **Jan WK1 (Jan 5)** through **Mar WK4 (Mar 20)** — 12 weekly scans, 115 picks tracked. 📷 Snapshot date: May 8, 2026 — all 45-day windows fully matured Q1 Key Insight The catalyst-driven thesis held through Q1: **—** of picks hit at least a 15% intraquarter gain within their 45-day post-pick window, and **—** reached 30%+. Yet only **—** are still green at the time of this snapshot. The gap is the **exit window** — the spike-and-fade dynamic these picks are designed to capture. Performance by Market Cap Tier | Tier | \# Picks | 45d Peak Avg | 45d ≥15% Hit | 45d Avg Low | Curr Avg | | ---- | -------- | ------------ | ------------ | ----------- | -------- | Monthly Breakdown Weekly Performance Hide split-adjusted weeks | Week ↕ | Date ↕ | \# ↕ | Curr Avg ↕ | Curr WR ↕ | 45d Peak Avg ↕ | 45d ≥15% ↕ | 45d Avg Low ↕ | | ------ | ------ | ---- | ---------- | --------- | -------------- | ---------- | ------------- | Individual Picks All Weeks 45d Peak % Current Return 45d Low % BSI Score Market Cap Desc Hide split-adjusted | Week | # | Ticker | Pick $ | MCap | BSI | Curr $ | Curr % | Days | 45d Peak % | 45d Low % | | ---- | - | ------ | ------ | ---- | --- | ------ | ------ | ---- | ---------- | --------- | Q1 2026 Quarterly Performance Report · Data from [BioStockInfo.com](https://www.biostockinfo.com/) · Updated May 8, 2026 Past performance does not guarantee future results. ⚡ = split-adjusted data. Not financial advice.